Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $85.00 | Total: $425.00 |
| 1 | 10 | $72.00 | Total: $720.00 |
| 1 | 25 | $61.00 | Total: $1,525.00 |
| 1 | 50 | $52.00 | Total: $2,600.00 |
| 1 | 100 | $45.00 | Total: $4,500.00 |
Overview
Rilzabrutinib (PRN1008) is a reversible covalent, selective, and orally active inhibitor of Bruton
Chemical Properties
| Molecular Formula | C36H40FN9O3 |
| Molecular Weight | 665.76 |
| CAS Numbers | 1575596-29-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC(C)(C=C(C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Smith PF, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017 Nov;83[11] 2367-2376.